Medications That Can Lengthen QT Interval

High-Risk Medications

• The European Heart Journal recommends that Class IA antiarrhythmics, such as quinidine, procainamide, and disopyramide, be used with caution due to their potential to prolong the QT interval 1, 2
• The European Heart Journal also notes that Class III antiarrhythmics, including sotalol, dofetilide, and ibutilide, can cause QT prolongation 1, 3
• Amiodarone, an antiarrhythmic medication, can cause marked QT prolongation but has a relatively lower risk of torsades de pointes compared to other antiarrhythmics, according to the European Heart Journal and Praxis Medical Insights 4, 1
• The European Heart Journal lists thioridazine, haloperidol, chlorpromazine, and pimozide as antipsychotics that can prolong the QT interval 1
• Macrolide antibiotics, such as clarithromycin, erythromycin, and azithromycin, can prolong the QT interval, as reported by the European Heart Journal and Praxis Medical Insights 4, 1
• Fluoroquinolones, including sparfloxacin, moxifloxacin, levofloxacin, and ciprofloxacin, can also cause QT prolongation, according to the European Heart Journal 1
• Antifungals like ketoconazole and other imidazole antimycotics can prolong the QT interval, as noted by the European Heart Journal and Praxis Medical Insights 4, 5
• The European Heart Journal reports that antimalarials, such as chloroquine, hydroxychloroquine, and halofantrine, can cause QT prolongation 4, 5
• Pentamidine, used for Pneumocystis pneumonia, can prolong the QT interval, according to the European Heart Journal 1, 5
• Antiemetics like ondansetron, dolasetron, domperidone, and droperidol can cause QT prolongation, as reported by the European Heart Journal and Pediatrics 1, 6
• Methadone can prolong the QT interval, according to Circulation 7
• Cisapride, which has been withdrawn from the US market, can cause QT prolongation, as noted by the European Heart Journal 5

Risk Factors for Torsades de Pointes

• The European Heart Journal identifies female gender as a risk factor for developing torsades de pointes 1
• Hypokalemia or hypomagnesemia can increase the risk of torsades de pointes, according to the European Heart Journal 1
• Bradycardia is a risk factor for torsades de pointes, as reported by the European Heart Journal 1
• Recent conversion from atrial fibrillation can increase the risk of torsades de pointes, according to the European Heart Journal 1
• Congestive heart failure is a risk factor for torsades de pointes, as noted by the European Heart Journal 1
• Baseline QT prolongation or congenital long QT syndrome can increase the risk of torsades de pointes, according to the European Heart Journal 1
• Advanced age is a risk factor for torsades de pointes, as reported by Praxis Medical Insights 4
• Concomitant use of multiple QT-prolonging drugs can increase the risk of torsades de pointes, according to the European Heart Journal 1
• Drug interactions that increase levels of QT-prolonging medications can also increase the risk of torsades de pointes, as noted by the European Heart Journal 1

Monitoring and Management

• Praxis Medical Insights recommends a baseline ECG before starting QT-prolonging medications 4
• QTc intervals >500 ms or increases >60 ms from baseline warrant immediate attention, according to Praxis Medical Insights 4
• Electrolyte monitoring, especially potassium and magnesium, is essential, as reported by the European Heart Journal and Praxis Medical Insights 4, 1
• Removal of the offending agent is indicated in patients with drug-induced LQTS, according to the European Heart Journal 1
• Consider alternatives with lower risk when possible for patients requiring QT-prolonging medications, as recommended by Praxis Medical Insights 4
• Intravenous magnesium can suppress episodes of torsades de pointes even when serum magnesium is normal, according to the European Heart Journal 1

Special Considerations

• Genetic polymorphisms can increase susceptibility to drug-induced QT prolongation, as reported by the European Heart Journal 5

Common Pitfalls and Caveats

• Not all QT prolongation leads to torsades de pointes, and the risk varies by medication, according to Circulation 7
• Amiodarone causes significant QT prolongation but has a relatively lower risk of torsades de pointes compared to other antiarrhythmics, as noted by Praxis Medical Insights 4
• Many medications not primarily prescribed for cardiac conditions can cause QT prolongation, according to Pediatrics 6
• Drug interactions can significantly increase the risk of QT prolongation, as reported by the European Heart Journal 1
• QT prolongation risk is dose-dependent for most medications, according to Circulation 7

QT Interval Prolongation in Hospitalized Patients

High-Risk Medications

• The American Heart Association recommends that thioridazine, intravenous haloperidol, and pimozide be used with caution due to their high risk of QT prolongation, with thioridazine causing 25-30 ms prolongation, intravenous haloperidol causing 7 ms prolongation, and pimozide causing 13 ms prolongation in hospitalized patients 8
• Amiodarone markedly prolongs QT but rarely causes torsades de pointes due to uniform repolarization delay across all myocardial layers in patients with existing heart conditions 8
• Tricyclic antidepressants, such as amitriptyline, cause more QT prolongation than SSRIs, particularly in overdose situations, with a mean increase in QT prolongation of 24 ms vs -1 ms with monotherapy 8
• Citalopram and escitalopram can prolong QT in patients with pre-existing cardiovascular disease 8
• Methadone is a high-risk medication for QT prolongation, with nearly 1 million Americans using it for narcotic dependence or chronic pain, and guidelines recommend pretreatment ECG, follow-up ECG within 30 days, and annual monitoring for methadone patients 8

Critical Risk Factors

• Female sex, age >65 years, baseline QTc >500 ms, hypokalemia, hypomagnesemia, bradycardia, and concomitant use of multiple QT-prolonging drugs are the most important risk factors for QT interval prolongation in hospitalized patients, according to the American College of Cardiology 8
• Electrolyte abnormalities, particularly potassium <4.5 mEq/L and low magnesium, must be corrected before initiating QT-prolonging medications to reduce the risk of torsades de pointes 8
• Pre-existing cardiovascular disease, heart failure, and left ventricular hypertrophy increase the risk of QT interval prolongation in patients taking QT-prolonging medications 8

Administration and Monitoring

• Intravenous administration carries higher risk than oral dosing due to greater cardiac drug exposure and rapid infusion rates, particularly for haloperidol, where IV route dramatically increases torsades risk compared to oral or IM administration, according to the American Heart Association 8

Medications and Drug Interactions Causing Increased PR and QTc Intervals

Medications That Prolong Both PR and QTc Intervals

• Verapamil and diltiazem prolong the PR interval through AV nodal blockade and when combined with QTc-prolonging drugs create additive risk, though they don't significantly prolong QTc as monotherapy, according to the Liver International guideline 9
• The combination of CYP3A4 inhibitors (azole antifungals, macrolides, protease inhibitors) with amiodarone or quinidine dramatically increases antiarrhythmic levels and both PR/QTc effects, as reported in Liver International 9
• The combination of ketoconazole with amiodarone is contraindicated due to severe risk of overdose and combined conduction abnormalities, as stated in Liver International 9
• Protease inhibitors increase amiodarone concentrations significantly through CYP3A4 inhibition, according to Liver International 9
• Combining amiodarone with other QTc-prolonging drugs (antipsychotics, macrolides, fluoroquinolones) is explicitly contraindicated due to additive repolarization effects, though PR prolongation remains primarily from amiodarone, as reported in Liver International 9

Medications That Cause QT Prolongation and Associated Risks

High-Risk Medications and Patient Factors

• The American Academy of Pediatrics recommends that haloperidol, given via IV route, has a dramatically higher risk of QT prolongation compared to oral or IM administration, with a mean QTc prolongation of 7 ms 10
• The American College of Cardiology suggests that concomitant use of multiple QT-prolonging drugs creates additive risk, and a detailed cardiac history, including family history of sudden cardiac death, should be obtained before initiating treatment 11
• The American College of Cardiology recommends reviewing the complete medication list for drug interactions that may increase levels of QT-prolonging medications through CYP3A4 inhibition 11
• The American Academy of Pediatrics notes that azithromycin causes dose-dependent QT prolongation, with specific FDA warnings about torsades de pointes risk 10
• The American Academy of Pediatrics states that trimethoprim-sulfamethoxazole causes QT prolongation through potassium channel blockade, with genetic polymorphisms significantly increasing individual susceptibility 10
• The American College of Cardiology advises that antihistamines, such as diphenhydramine, hydroxyzine, and loratadine, can cause QT prolongation and should be used with caution 10
• The American Academy of Pediatrics warns that respiratory medications, such as albuterol, terbutaline, and phenylephrine, can cause QT prolongation and should be used with caution 10
• The American College of Cardiology recommends that cardiac medications, such as adenosine, dopamine, epinephrine, and dobutamine, can cause QT prolongation and should be used with caution 10

Monitoring and Management

• The American College of Cardiology suggests that a baseline ECG should be obtained to measure QTc interval in all patients before initiating QT-prolonging medications, and a follow-up ECG should be performed after dose titration or within 30 days for high-risk medications 11
• The American Academy of Pediatrics recommends that electrolytes, particularly potassium and magnesium, should be checked regularly to maintain potassium >4.5 mEq/L 10

Medications That Cause QT Prolongation

High-Risk Drug Categories

• Erythromycin carries the highest risk among macrolides, particularly with IV administration, and moxifloxacin causes more common QTc prolongation in hypokalaemia and proarrhythmic conditions, according to the Thorax journal 12
• Moxifloxacin, levofloxacin, and ciprofloxacin cause QT prolongation, and the Thorax journal notes that moxifloxacin requires careful monitoring in high-risk patients 12
• Antimalarial drugs, including chloroquine, hydroxychloroquine, mefloquine, quinine, and halofantrine, cause QT prolongation, as reported in the Thorax journal 12
• Pentamidine significantly prolongs the QT interval, and the Thorax journal recommends cautious use in patients with pre-existing QT prolongation 12
• 5-HT3 antagonists, including ondansetron, granisetron, and dolasetron, carry FDA warnings for QT prolongation, and the Thorax journal advises careful monitoring in high-risk patients 12
• Metoclopramide prolongs the QT interval and should be used with extreme caution, according to the Thorax journal 12
• Domperidone prolongs QTc and should be avoided entirely in at-risk patients, as noted in the Thorax journal 12
• Saquinavir increases ventricular arrhythmia risk, and the Thorax journal recommends careful monitoring in patients with pre-existing QT prolongation 12

Guideline‑Based Assessment and Management of QT‑Prolongation Risk with Antipsychotic Therapy

Drug Lists and Status of Caplyta (lumateperone)

• The American College of Cardiology/American Heart Association/Heart Rhythm Society (ACC/AHA/HRS) QT‑prolonging drug lists (2006) do not include lumateperone (Caplyta) as a known QT‑prolonging agent. 13
• The European Heart Journal’s comprehensive catalogs of QT‑prolonging medications (2014; 2001) likewise omit Caplyta, indicating it is not recognized as a well‑established QT‑prolonging drug. 14

Pre‑Treatment Assessment

• Obtain a baseline 12‑lead ECG to measure the QTc interval before initiating any antipsychotic therapy. 14, 15
• Correct electrolyte abnormalities before starting treatment: maintain serum potassium > 4.5 mEq/L and normalize magnesium levels. 13, 16, 15
• Review the patient’s complete medication list for other QT‑prolonging drugs or strong CYP3A4 inhibitors that could increase antipsychotic levels. 14
• Collect a detailed cardiac history, including personal or family history of sudden cardiac death, congenital long QT syndrome, syncope, or structural heart disease. 14, 15

Identification of High‑Risk Patients

• High‑risk factors for drug‑induced QT prolongation identified by ACC/AHA/HRS and the European Society of Cardiology include: female sex, age > 65 years, baseline QTc > 500 ms (absolute contraindication), baseline QTc > 450 ms in men or > 460 ms in women, hypokalemia or hypomagnesemia, bradycardia or recent conversion from atrial fibrillation, congestive heart failure or other structural heart disease, congenital long QT syndrome (or family history), and concurrent use of other QT‑prolonging medications. 13, 16, 14

Monitoring Thresholds and Follow‑Up ECG

• QTc ≥ 500 ms – discontinue all QT‑prolonging medications immediately. 14, 15
• QTc increase > 60 ms from baseline – stop the offending antipsychotic regardless of the absolute QTc value. 14, 15
• QTc 450–499 ms – consider switching to a low‑risk antipsychotic (e.g., aripiprazole) and repeat ECG 7–15 days after initiation or any dose change. 14
• Perform a follow‑up ECG within 1–2 weeks (approximately five drug half‑lives, steady‑state) after starting any Class B psychotropic medication and after any significant dose increase. 14

Management of Drug‑Induced QT Prolongation / Torsades de Pointes

• Immediate discontinuation of the offending agent is a Class I recommendation (Level A evidence). 13, 16
• IV magnesium sulfate 1–2 g should be administered promptly; it can suppress torsades even when serum magnesium is normal. (Evidence cited in the same ACC/AHA/HRS sources.) 13, 16
• Potassium repletion to 4.5–5 mEq/L is a Class IIb recommendation. 16
• For recurrent torsades, temporary cardiac pacing or isoproterenol infusion is a Class IIa recommendation. (Supported by the ACC/AHA/HRS guidelines.) 13, 16

Avoidance of Common Pitfalls

• Do not combine multiple QT‑prolonging antipsychotics without expert cardiology consultation, as this exponentially raises the risk of torsades. 14

Management of Life‑Threatening QTc Prolongation (>500 ms)

Immediate Actions

• Discontinue all QT‑prolonging medications without delay in any patient whose corrected QT interval exceeds 500 ms, as this is an absolute contraindication for adding further QT‑prolonging agents. 17
• Correct electrolyte abnormalities urgently, targeting serum potassium > 4.5 mmol/L (optimal 4.5–5.0 mmol/L) and normalizing magnesium levels, to reduce the risk of torsades de pointes. 17

Cardiology Involvement

• Obtain a cardiology consultation promptly; consider temporary cardiac pacing if recurrent ventricular arrhythmias develop despite medication withdrawal and electrolyte correction. 17

Medication Review – QT‑Prolonging Agents

• Antiarrhythmic drugs quinidine, procainamide, sotalol, and amiodarone are recognized QT‑prolonging agents and should be removed or substituted when a QTc > 500 ms is present. 17

Safety of Specific Drugs in Controlled QTc

• Gabapentin is not listed among medications that prolong the QT interval in major cardiology guidelines, indicating it can be used safely once the QTc has been reduced below the high‑risk threshold. 17

Management of Drug‑Induced QT Prolongation in Hospitalized Older Adults

High‑Risk Medication Categories

• Class IA antiarrhythmics (e.g., quinidine, procainamide, disopyramide) and Class III agents (e.g., sotalol, dofetilide, ibutilide) are among the most potent QT‑prolonging drugs. 18
• Macrolide antibiotics, especially intravenous erythromycin, carry the highest QT‑prolongation risk among this class, followed by clarithromycin and azithromycin. 18
• Fluoroquinolones rank in descending QT risk as moxifloxacin > levofloxacin > ciprofloxacin. 18
• Azole antifungals (e.g., ketoconazole) and the antiprotozoal pentamidine significantly prolong QTc. 18
• High‑risk antipsychotics include thioridazine (≈ 25‑30 ms QT increase, FDA black‑box warning), haloperidol (≈ 7 ms, markedly higher with IV use), and pimozide (≈ 13 ms). 18
• Moderate‑risk antipsychotics such as ziprasidone, quetiapine, and clozapine produce smaller QTc increases (≈ 5‑10 ms). 18
• Tricyclic antidepressants cause greater QT prolongation than SSRIs, especially in overdose settings (average ≈ 24 ms increase). 18
• Common non‑cardiac QT‑prolonging agents include ondansetron, dolasetron, domperidone, droperidol (all with FDA warnings), methadone, and antimalarials (chloroquine, hydroxychloroquine, halofantrine). 18

Patient‑Specific Risk Factors

• Female sex markedly increases susceptibility to drug‑induced torsades de pointes. 19
• Age > 65 years is an independent predictor of QT‑related arrhythmia. 19
• Structural heart disease (e.g., heart failure, prior myocardial infarction, left‑ventricular hypertrophy) dramatically raises torsades risk. 19
• Electrolyte disturbances amplify risk exponentially:
  
  • Hypokalemia (serum K⁺ < 4.5 mmol/L)
  • Hypomagnesemia (even when serum Mg²⁺ appears normal)
  • Hypocalcemia
• Bradycardia or rhythm pauses create a “short‑long‑short” sequence that can trigger torsades. 19

QTc Thresholds Guiding Immediate Action

• QTc > 500 ms → discontinue all QT‑prolonging medications immediately. 19
• QTc increase > 60 ms from baseline → stop offending agents regardless of absolute QTc value. 19
• QTc 450‑499 ms → heightened monitoring and consideration of medication adjustment. 19

Immediate Management of Established QT Prolongation (Class I Recommendations)

• Discontinue the offending drug(s) without delay. 19
• Administer intravenous magnesium sulfate 1‑2 g (even if serum magnesium is normal) for its membrane‑stabilizing effect. 19
• Replete potassium to a target of 4.5‑5.0 mmol/L (ideally 4.5‑5.0 mmol/L). 19
• Transfer the patient to a setting with continuous cardiac monitoring and immediate defibrillation capability. 19

Strategies for Recurrent Torsades

• Temporary cardiac pacing (Class IIa) to prevent bradycardia‑related pauses. 19
• If pacing is unavailable, initiate an isoproterenol infusion. 19

Medication Review and Interaction Mitigation

• Use an up‑to‑date QT‑prolonging drug list (e.g., qtdrugs.org) to identify every offending agent. [18][19]
• Avoid concurrent use of QT‑prolonging drugs whenever possible; seek cardiology consultation for necessary combinations. 19
• Recognize that CYP3A4 inhibitors (ketoconazole, erythromycin, protease inhibitors) can raise plasma levels of QT‑prolonging agents such as amiodarone or quinidine, further increasing risk. 19

Route‑of‑Administration Considerations

• Intravenous administration markedly raises torsades risk compared with oral or intramuscular routes, especially for haloperidol and erythromycin. 19
• Rapid IV infusion further escalates the danger. 19

Monitoring Protocol

• Obtain a baseline ECG before starting any QT‑prolonging medication. 19
• Repeat ECG 7‑15 days after initiation or after any dose change. 19
• Perform serial electrolyte checks throughout therapy, with particular attention in patients receiving diuretics. 19
• Use a consistent QT measurement method (same lead, same correction formula) for serial comparisons. 19

Safer Therapeutic Alternatives

• For agitation, prefer benzodiazepines (e.g., lorazepam) which do not affect QTc. 19
• When antipsychotic therapy is required, consider aripiprazole (no QTc prolongation) over haloperidol, quetiapine, or olanzapine. 19
• Opt for non‑macrolide, non‑fluoroquinolone antibiotics when clinically appropriate. 19

Cardiac Potassium (hERG/IKr) versus Sodium (Nav1.5) Channel Blockade in Drug‑Induced QT Prolongation

Mechanistic Overview

• hERG (IKr) blockade is the principal cause of drug‑induced QTc prolongation, whereas therapeutic Nav1.5 (sodium‑channel) blockade acts as a protective modulator that can attenuate QTc lengthening and reduce arrhythmia risk. The European Society of Cardiology highlights this distinction, noting that potassium‑channel inhibition drives repolarisation delay while concurrent sodium‑channel inhibition may offset it【20】【21】.

Antipsychotic Medications

• All antipsychotic agents prolong the QT interval by inhibiting the IKr current through hERG‑encoded channels. This effect is observed across the class regardless of individual drug potency, as reported by the European Society of Cardiology【20】【21】.

Antibiotic‑Related QT Risk

• Macrolide antibiotics, especially intravenous erythromycin, carry the greatest QTc‑prolonging risk among this class. The European Society of Cardiology quantifies the effect and advises heightened vigilance for IV use【22】.

Sodium‑Channel Toxicity in Overdose

• In overdose, tricyclic antidepressants produce wide QRS complexes, sinusoidal ventricular tachycardia, and other life‑threatening arrhythmias primarily via dominant sodium‑channel toxicity rather than hERG blockade【23】.
• Class IA antiarrhythmic drugs can precipitate conduction disturbances (e.g., prolonged QRS, atrioventricular block) through their sodium‑channel effects when present in toxic concentrations【23】.
• Cocaine toxicity includes a significant sodium‑channel blockade component, contributing to its pro‑arrhythmic profile【23】.

Management of Sodium‑Channel Blocker Overdose

• Administration of sodium chloride or sodium bicarbonate boluses is recommended to reverse conduction slowing and treat cardioversion‑resistant ventricular tachycardia caused by sodium‑channel blocker toxicity【23】.
• Beta‑blockers have been successfully employed as adjunct therapy in cases of sodium‑channel blocker toxicity【23】.

QT Prolongation Risk Management

Spironolactone and QT Risk

• Spironolactone does not prolong the QT interval and may lower the likelihood of drug‑induced torsades de pointes by correcting low potassium and magnesium levels, as reported by the American College of Cardiology (2017) 24.

Electrolyte Optimization and Baseline Risk Assessment

• Maintaining potassium in the high‑normal range and ensuring normal magnesium concentrations is advised to reduce QT‑prolongation risk (American College of Cardiology, 2017) 24.
• Recognized baseline risk factors for QT prolongation include female sex, age > 65 years, structural heart disease, bradycardia, and congenital long‑QT syndrome (American College of Cardiology, 2017) 24.

QTc Prolongation Risk and Management of Nortriptyline

Magnitude of QTc Prolongation

• Nortriptyline modestly prolongs the QTc interval at therapeutic doses; clinically significant prolongation (> 500 ms or an increase > 60 ms from baseline) is uncommon in patients without additional risk factors. European Society of Cardiology guidance. 25
• In patients receiving typical analgesic dosing (≈ 10 mg/day), the mean QTc increased from 413 ms to 420 ms (≈ 6–7 ms), and no individual exceeded the 500‑ms safety threshold or showed a ΔQTc > 60 ms. European Society of Cardiology data. 25
• Compared with selective serotonin reuptake inhibitors, tricyclic antidepressants cause greater QTc prolongation and raise the risk of cardiac arrest (odds ratio 1.69). Nortriptyline specifically was associated with higher mortality (OR 4.60; 95 % CI 1.20–18.40) in large observational cohorts. European Society of Cardiology evidence (observational). 25

Patient‑Specific Risk Factors

• Female sex and age > 65 years each double the risk of torsades de pointes when nortriptyline is used. American Heart Association findings. [26][27]25
• A baseline QTc > 500 ms constitutes an absolute contraindication to initiating nortriptyline therapy. American Heart Association recommendation. 26
• Electrolyte disturbances—serum potassium < 4.5 mmol/L or magnesium deficiency—exponentially increase arrhythmia risk and should be corrected before treatment. American Heart Association guidance (moderate evidence). [26][27]
• Concomitant use of other QT‑prolonging agents (e.g., antipsychotics, macrolide antibiotics, fluoroquinolones, methadone) markedly amplifies torsades risk. American Heart Association and European Society of Cardiology advisories. [26][27]25
• Underlying structural heart disease (heart failure, prior myocardial infarction, bradycardia) significantly heightens vulnerability to QTc‑related events. American Heart Association data. [26][27]

Pre‑Treatment Assessment and Monitoring Protocol

• Baseline ECG: Obtain a 12‑lead ECG before starting nortriptyline; do not initiate therapy if QTc > 500 ms or if QTc > 450 ms in men or > 460 ms in women without cardiology consultation. American Heart Association protocol. 26
• Electrolyte optimization: Ensure serum potassium > 4.5 mmol/L and normalize magnesium levels prior to therapy. American Heart Association recommendation (moderate evidence). [26][27]
• Medication review: Screen for other QT‑prolonging drugs and CYP450 inhibitors that could raise nortriptyline concentrations. American Heart Association and European Society of Cardiology guidance. [27][25]

Ongoing Monitoring

• ECG follow‑up: Repeat the ECG 7–15 days after initiation or after any dose change, then monthly for the first three months. (Protocol derived from clinical practice; no specific citation required.)
• Immediate discontinuation: Stop nortriptyline promptly if QTc exceeds 500 ms or rises > 60 ms from baseline. American Heart Association safety directive. 26
• Electrolyte surveillance: Monitor potassium and magnesium regularly, especially in patients receiving diuretics. American Heart Association recommendation (moderate evidence). [26][27]

Safer Therapeutic Alternatives When QTc Concerns Exist

• Selective serotonin reuptake inhibitors (SSRIs) produce less QTc prolongation than tricyclic agents; however, citalopram and escitalopram require dose limits in older adults. European Society of Cardiology guidance. 25

Critical Drug‑Interaction Pitfalls

• Avoid co‑administration with Class B antipsychotics such as thioridazine or haloperidol, as this combination exponentially raises the risk of torsades de pointes. European Society of Cardiology warning. 25